APSR2026-143

 
Late-Breaking
Submitted
Poster Presentation
 
AP01-001
P01
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1210684-46904-Mitsuo Sato APSR26_Poste %23143_432247.pdf
Format: PDF Only
02. Cell and Molecular Biology
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Mitsuo Sato * Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Ayana Iwabe - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Nozomi Kawabe - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Masahito Katsuda - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Shinnosuke Kato - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Ichidai Tanaka - Nagoya University Graduate School of Medicine Dept. of Respiratory Medicine Nagoya Japan
Miyoko Matsushima - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
Tsutomu Kawabe - Nagoya University Graduate School of Medicine Division of Host Defense Sciences, Dept. of Integrated Health Sciences Nagoya Japan
 
 
 
 
 
 
 
Presenting Author Details
Mitsuo
Sato
sato.mitsuo.e1@f.mail.nagoya-u.ac.jp
+81906091341
51-60
Japan
Original Research
Knockdown of Gene Y, Upregulated by Mutant KRAS or EGFR, Inhibits the Growth of Lung Cancer Cells
Maximum 25 words
Abstract Content
Mutant KRAS is the most frequent driver oncogene in lung cancer, yet only a few molecularly targeted drugs with limited clinical efficacy are available. This study aimed to identify potential therapeutic targets other than mutant KRAS itself for KRAS-driven lung cancer.
Next-generation RNA sequencing was performed using an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line (HBEC3-RIN2) with doxycycline dose-dependent induction of KRASV12 to identify genes upregulated after KRAS activation. Among the upregulated genes, we focused on Gene Y, whose oncogenic role has been suggested in several solid cancers, but remains unclear in lung cancer and in relation to specific driver oncogenes. Protein Y expression was examined across KRAS- and EGFR-mutant lung cancer cell lines and compared with normal controls. Gene Y induction was also evaluated in additional inducible HBEC models expressing EGFRL858R (HBEC3-EIN) or BRAFV600E (HBEC3-BIN). Functional effects of Gene Y knockdown were assessed in KRASV12-inducible HBEC3-RIN2 cells (KRAS on/off conditions) and in lung cancer cell lines (proliferation and colony formation assays). Mechanistic studies evaluated whether Gene Y induction was linked to EGFR pathway activation.
RNA sequencing identified Gene Y as a KRAS-inducible candidate target. Protein Y was increased in a subset of KRAS- and EGFR-mutant lung cancer cell lines compared with normal controls. In inducible HBEC models, Gene Y was upregulated in EGFR L858R-expressing HBEC3-EIN cells but not in BRAF V600E-expressing HBEC3-BIN cells. Gene Y knockdown more strongly suppressed growth in KRASV12-expressing HBEC3-RIN2 cells than in non-expressing cells, indicating increased dependency on Gene Y under KRASV12 induction. Gene Y knockdown also suppressed proliferation and colony formation in three KRAS-mutant and one EGFR-mutant lung cancer cell line. Mechanistically, Gene Y was induced by activation of EGFR signaling, suggesting that mutant KRAS–associated upregulation of Gene Y may occur through EGFR-related downstream signaling pathways.
Gene Y is upregulated downstream of major oncogenic drivers (KRAS and EGFR) and is required for optimal growth of multiple lung cancer cell lines. These findings suggest that Gene Y may represent a potential therapeutic target for both KRAS- and EGFR-mutant lung cancers.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
KRAS-mutant lung cancer, EGFR signaling, Therapeutic target
maximum 3 keywords and no abbreviations, separated by commas
Authors do not have COI to declare.
338